.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Anti-VEGF therapy in India has fundamentally altered the management of retinal vascular disorders over the last two decades. Traditionally, laser photocoagulation was the primary treatment for conditions like diabetic macular edema. However, the discovery of Vascular Endothelial Growth Factor as a central driver of neovascularization changed clinical practice. Early agents like pegaptanib paved the way for more potent molecules. Furthermore, the development of ranibizumab and aflibercept provided clinicians with highly effective tools to preserve vision and improve patient outcomes.
The Indian healthcare landscape presents unique economic challenges for patients requiring long-term retinal care. Consequently, the high cost of innovator biologics often limits treatment adherence in many cases. To address this, India pioneered the use of biosimilar ranibizumab to improve affordability. These biosimilars offer similar efficacy and safety profiles compared to their reference products. Moreover, they significantly reduce the financial burden on families. In addition, off-label bevacizumab remains a widely used, cost-effective alternative in many clinical settings across the country.
Clinicians must maintain strict safety standards when administering intravitreal injections. Specifically, monitoring for endophthalmitis and intraocular pressure spikes is essential. Newer bispecific antibodies like faricimab now offer the potential for extended dosing intervals. This advancement may reduce the treatment burden for patients with age-related macular degeneration. Ultimately, providing high-quality retinal care requires a balance between innovation and equitable access for the diverse Indian population.
The most common agents include ranibizumab, aflibercept, brolucizumab, and faricimab. Additionally, biosimilar ranibizumab and off-label bevacizumab are frequently utilized due to cost considerations.
Biosimilars have made advanced retinal therapy more accessible to a larger segment of the population. By reducing the price of therapy by 35% to 50%, they help improve long-term treatment compliance for chronic conditions.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Verma L et al. Peep into anti-vascular endothelial growth factor. Indian J Ophthalmol. 2026 May 01. doi: 10.4103/IJO.IJO_385_26. PMID: 42060349.
Sharma A et al. Biosimilar anti-VEGF: transforming retina treatment economics in South Asia. Gabionline.net (2023).
Pramanik S et al. Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population. Dove Medical Press (2021).
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A comprehensive guide on anti-VEGF agents in India, discussing their evolution, clinical use, and the pivotal role of biosimilars in treating retinal diseas...
4 months ago
A large NHANES cohort study reveals that higher Healthy Eating Index scores significantly reduce all-cause mortality risk in CKD patients by 45%. This analysis highlights the importance of comprehensive diet quality and medical nutrition therapy in renal care to optimize long-term clinical survival.
Today
A prospective cohort study demonstrates that poor adolescent sleep quality, especially long sleep latency and reduced efficiency, increases dysmenorrhea severity in young adulthood. Addressing adolescent rest patterns offers a critical preventive avenue for clinicians.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Today
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
